Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib

BACKGROUND: Crizotinib is the first tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC). An increased incidence of renal cysts has been described during the crizotinib treatment. CASE PRESENTATION: We herein report th...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int Med Case Rep J
Main Authors: Di Marino, Pietro, Mannetta, Gianluca, Carella, Consiglia, Grassadonia, Antonino, Tinari, Nicola, Natoli, Clara, De Tursi, Michele
Formato: Artigo
Idioma:Inglês
Publicado: Dove 2020
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7083626/
https://ncbi.nlm.nih.gov/pubmed/32214855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IMCRJ.S229080
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares